The Pharmacological Guide to Metformin


Natalie Lajoie (Editor)

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Almost six decades after its discovery, metformin still remains the gold standard drug for the management of type 2 diabetes mellitus, owing to its euglycemic property and cost-effectiveness. It is the most commonly prescribed and utilized oral antidiabetic drug worldwide. However, no two persons with the same phenotypical characteristics, such as age, gender, body weight and others, tend to respond similarly to equivalent doses of metformin. As such, The Pharmacological Guide to Metformin first focuses on the various genetic polymorphisms that influence the therapeutic effects of metformin.

Physicochemical, pharmacological, and pharmacokinetic properties of metformin will also be reviewed.

The side effects of this drug can be dangerous. Metformin-induced lactic acidosis is a lethal disorder. The first significant deviation is gastrointestinal tract involvement. Common infection or the effect of metformin itself causes vomiting and diarrhea, with subsequent hypovolemia causing pre-renal acute kidney injury, which in turn raises metformin levels up to toxic values. Development of kidney failure is often unexpected and fast.

Following this, the authors explore the differences between healthy and cancer cells and how this may influence the metformin effect on these cells.

In conclusion, the molecular mechanisms underlying the anticancer effects of metformin in breast and ovarian cancers are summarized, and the potential anticancer applications of metformin-based combinatorial chemotherapy are discussed.
(Imprint: Nova Medicine and Health)

Table of Contents

Table of Contents


Chapter 1. The Pharmacogenetics of Metformin
(Gerard Marshall Raj and Saranya Vilvanathan, Sri Venkateshwaraa Medical College Hospital and Research Centre, Puducherry, India, and Medical University of the Americas, Charlestown, Nevis, Saint Kitts and Nevis, West Indies)

Chapter 2. Physicochemical and Pharmacokinetic Properties of Metformin Hydrochloride
(Selma Sahin, PhD, and Tugba Gulsun, PhD, Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey)

Chapter 3. Metformin: Who Are Suitable Patients?
(Karel Kubát MD, Department of Internal Medicine, Litomerice Hospital, Litomerice, Czech Republic)
Free Download Available

Chapter 4. Metformin Effects in Cancer Models
(André Gustavo de Oliveira, PhD, Maria Cristina C. Gomes-Marcondes, PhD, Obesity and Comorbidities Research Centre, Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, SP, Brazil, and others)

Chapter 5. The Therapeutic Potential of Metformin in Breast and Ovarian Cancer
(Isabella dos Santos Guimarães, Diandra Zipinotti dos Santos, Paulo CM Lyra-Junior, Ian Victor Silva and Leticia Batista Azevedo Rangel, Clinical Research Division, Brazilian National Cancer Institute, Rio de Janeiro, Brazil)


Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!